ITD-FLT3 mutations in human AML stem cells are present in 20–30% of AML patients and have been implicated in the poor prognosis and refractory phenotype of this disease [77,78,79,80,81,82]. This evidence concerns the gene FLT3 and acute myeloid leukemia.